Published in Lupus on January 01, 2003
Antiphospholipid Syndrome during pregnancy: the state of the art. J Prenat Med (2011) 1.02
Managing pregnancy in inflammatory rheumatological diseases. Arthritis Res Ther (2011) 0.86
Indications for IVIG in rheumatic diseases. Rheumatology (Oxford) (2014) 0.77
Management of antiphospholipid syndrome. Ther Adv Musculoskelet Dis (2010) 0.76
Immunomodulatory effects of therapeutic plasma exchange on monocytes in antiphospholipid syndrome. Exp Ther Med (2016) 0.75
Therapeutic management of antiphospholipid syndrome in aspirin sensitive patients. Lupus (2004) 0.75
Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation. Clin Rheumatol (2004) 0.75
[Systematic lupus erythematosus and antiphospholipid syndrome during pregnancy]. Z Rheumatol (2006) 0.75
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum (1999) 7.67
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet (1999) 7.04
Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. N Engl J Med (1983) 4.43
Cultivation of the bacillus of Whipple's disease. N Engl J Med (2000) 3.97
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus (2003) 3.61
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Systemic capillary leak syndrome: report on 13 patients with special focus on course and treatment. Am J Med (1997) 3.01
Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med (1983) 2.96
Possible mechanisms of emphysema in smokers. In vitro suppression of serum elastase-inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants. Am Rev Respir Dis (1978) 2.90
Rheumatology in Israel. Br J Rheumatol (1996) 2.66
Serum antibodies in epilepsy and seizure-associated disorders. Neurology (2005) 2.53
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) (2005) 2.37
Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) (2000) 2.35
Evaluation of a commercial enzyme-linked immunosorbent assay for detection of herpes simplex virus antigen. J Clin Microbiol (1984) 2.34
Colonic response to dietary fibre from carrot, cabbage, apple, bran. Lancet (1978) 2.33
Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet (1998) 2.31
The key role of nucleosomes in lupus. Arthritis Rheum (1999) 2.26
Production of autoantibodies by human-human hybridomas. J Clin Invest (1982) 2.22
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
In vitro suppression of serum elastase-inhibitory capacity by reactive oxygen species generated by phagocytosing polymorphonuclear leukocytes. J Clin Invest (1979) 2.15
Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med (1996) 2.10
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice. Pathogenetic role in experimental vasculitis. Arthritis Rheum (1995) 2.09
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med (1982) 2.04
Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) (2001) 2.02
Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) (1998) 2.01
Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci U S A (1982) 1.99
Systemic lupus erythematosus and the antiphospholipid syndrome: reflections about the relevance of ARA criteria. J Rheumatol (1992) 1.94
Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis (1984) 1.93
Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation (1996) 1.92
Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A (1988) 1.91
Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation (1998) 1.87
Arterial lesions in Behçet's disease. A study in 25 patients. J Rheumatol (1995) 1.85
Potential mediator of inflammation. Phagocyte-derived oxidants suppress the elastase-inhibitory capacity of alpha 1-proteinase inhibitor in vitro. J Clin Invest (1980) 1.85
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum (1999) 1.77
Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A (1991) 1.77
Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol (1984) 1.76
Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut (2005) 1.73
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology (1994) 1.69
Cigarette smoke inhalation decreases alpha 1-antitrypsin activity in rat lung. Science (1979) 1.68
Poly(ADP-ribose) polymerase alleles in French Caucasians are associated neither with lupus nor with primary antiphospholipid syndrome. GRAID Research Group. Group for Research on Auto-Immune Disorders. Arthritis Rheum (1999) 1.67
Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr (2005) 1.66
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
Pacemaker infective endocarditis. Am J Cardiol (1998) 1.62
No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol (1996) 1.58
Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation (2000) 1.58
Lung injury induced by leukocytic proteases. Am J Pathol (1979) 1.56
Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum (1997) 1.55
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis (2001) 1.55
Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) (1990) 1.55
Intractable hiccup as the initial presenting feature of systemic lupus erythematosus. Lupus (2005) 1.53
Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum (1984) 1.53
Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis (2004) 1.53
Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis (2010) 1.52
Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum (2000) 1.52
Immunologic and genetic factors in autoimmune diseases. N Engl J Med (1984) 1.50
Elevated homocysteine levels in patients with Raynaud's syndrome. J Rheumatol (1999) 1.49
Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol (2001) 1.49
Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med (1991) 1.49
The prevalence of coeliac disease antibodies in patients with the antiphospholipid syndrome. Lupus (2003) 1.48
Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum (1985) 1.48
Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2003) 1.48
Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis (2005) 1.48
Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant (1998) 1.47
A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol (2001) 1.46
Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology (1995) 1.46
Urinary trypsin inhibitory activity for the diagnosis of bacterial infection: a prospective study in 690 patients. Eur J Med (1992) 1.45
Autoantibodies in neoplasia. An unresolved enigma. Cancer (1990) 1.45
The effect of patient position and obesity on the spread of epidural analgesia. Int J Obstet Anesth (1993) 1.45
Cerebral venous thrombosis in systemic lupus erythematosus. Stroke (1990) 1.45
Role of beta 2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus (1995) 1.44
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut (1999) 1.44
The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol (1999) 1.44
The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome--molecular mimicry? J Rheumatol (2000) 1.44
Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis (2005) 1.44
Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell. Arthritis Rheum (1995) 1.44
A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. Arthritis Rheum (2001) 1.43
The good, the bad and the ugly of vaccination. Isr Med Assoc J (2000) 1.43
Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) (2001) 1.43
T lymphocyte subsets in primary antiphospholipid syndrome. J Rheumatol (1994) 1.43
Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum (1997) 1.42
Clinical characteristics of ruptured chordae tendineae in hospitalized patients: primary tear versus infective endocarditis. Clin Cardiol (1998) 1.42
Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. J Rheumatol (2001) 1.41
A multidimensional autoantibody analysis specifying systemic lupus erythematosus patients with neuropsychiatric symptomatology. Isr J Med Sci (1992) 1.41
Etoposide in Wegener's granulomatosis. Rheumatology (Oxford) (1999) 1.40
Evaluation of the modified Chlamydiazyme immunoassay for the detection of chlamydial antigen. Am J Clin Pathol (1986) 1.40
Presence of a 16/6 related human anti-DNA common idiotype (SA1) in the anticardiolipin antibodies of patients with primary antiphospholipid syndrome. J Rheumatol (1991) 1.40
[Antiphospholipid antibodies: cause of thrombosis or an epiphenomenon?]. Presse Med (1995) 1.40